Reputable billionaire investors such as Nelson Peltz and David Tepper generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in investable assets would be required ...

Is Stemline Therapeutics Inc (NASDAQ:STML) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top ...

Investors are always looking for stocks that are poised to beat at earnings season and Stemline Therapeutics, Inc. STML may be one such company. The firm has earnings coming up pretty soon, and events ...

Find the latest Stemline Therapeutics, Inc. (STML) stock analysis from Seeking Alpha’s top analysts: exclusive research and insights from bulls and bears.

Stemline Therapeutics (STML) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of $0.92 per share a year ago. These ...

STML’s promoter Goldleaf International, promoter Sanjay Gupta, promoter and director Ajay Gupta promoter, director Kajal Rai and the company’s joint account holder Ram Lal Gupta have been barred.

A high-level overview of Stemline Therapeutics, Inc. (STML) stock. View (STML) real-time stock price, chart, news, analysis, analyst reviews and more.